(Q35129374)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12751918%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

review article

1 reference

title

Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12751918%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12751918%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

author name string

Teus van Laar

series ordinal

1

1 reference

6 August 2017

1 January 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12751918%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12751918%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12751918%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12751918%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

page(s)

475-489

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12751918%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/00023210-200317070-00002

3 November 2019

exact match

0 references

1 reference

12 December 2020

Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease

1 reference

12 December 2020

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

1 reference

12 December 2020

Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson's disease

1 reference

12 December 2020

Response fluctuations in Parkinson's disease

1 reference

12 December 2020

Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography

1 reference

12 December 2020

Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study

1 reference

12 December 2020

Comparative Review of Dopamine Receptor Agonists in Parkinson's Disease

1 reference

12 December 2020

Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.

1 reference

12 December 2020

1 reference

12 December 2020

Levodopa ethylester: a novel rescue therapy for response fluctuations in Parkinson's disease.

1 reference

12 December 2020

Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.

1 reference

12 December 2020

Current management of motor fluctuations in patients with advanced Parkinson's disease treated chronically with levodopa.

1 reference

12 December 2020

Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease

1 reference

12 December 2020

Dopamine agonists in Parkinson's disease.

1 reference

12 December 2020

Delayed onset of responses to single doses of L-dopa in parkinsonian fluctuators on long-term L-dopa therapy

1 reference

12 December 2020

Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease

1 reference

12 December 2020

1 reference

12 December 2020

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

1 reference

12 December 2020

Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study

1 reference

12 December 2020

Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys

1 reference

12 December 2020

Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I

1 reference

12 December 2020

Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.

1 reference

12 December 2020

Dystonic foot response of Parkinsonism

1 reference

12 December 2020

Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II.

1 reference

12 December 2020

Dystonia in Parkinson's disease: clinical and pharmacological features

1 reference

12 December 2020

Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations

1 reference

12 December 2020

A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease

1 reference

12 December 2020

Young-onset Parkinson's disease: a clinical review

1 reference

12 December 2020

Time course of tolerance to apomorphine in parkinsonism

1 reference

12 December 2020

Which risk factors predict the levodopa response in fluctuating Parkinson's disease?

1 reference

12 December 2020

Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias

1 reference

12 December 2020

A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease

1 reference

12 December 2020

Early-morning dystonia. A late side effect of long-term levodopa therapy in Parkinson's disease

1 reference

12 December 2020

Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience.

1 reference

12 December 2020

Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom

1 reference

12 December 2020

Implantable venous access system for apomorphine infusion in complicated Parkinson's disease

1 reference

12 December 2020

A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.

1 reference

12 December 2020

Intranasal apomorphine in parkinsonian on-off fluctuations

1 reference

12 December 2020

"Off period" dystonia and "on period" choreoathetosis in levodopa-treated patients with Parkinson's disease

1 reference

12 December 2020

The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.

1 reference

12 December 2020

Success and problems of long-term levodopa therapy in Parkinson's disease

1 reference

12 December 2020

The selective dopamine D1 receptor agonist, SKF 81297, stimulates motor behaviour of MPTP-lesioned monkeys

1 reference

12 December 2020

The role of dopamine agonists in early Parkinson's disease

1 reference

12 December 2020

Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding.

1 reference

12 December 2020

Deep brain stimulation for movement disorders

1 reference

12 December 2020

Amantadine treatment is an independent predictor of improved survival in Parkinson's disease.

1 reference

12 December 2020

Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients.

1 reference

12 December 2020

Episodic unresponsiveness to single doses of L-dopa in parkinsonian fluctuators

1 reference

12 December 2020

Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.

1 reference

12 December 2020

Pathophysiology of the basal ganglia in Parkinson's disease.

1 reference

12 December 2020

Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease

1 reference

12 December 2020

Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.

1 reference

12 December 2020

Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I

1 reference

12 December 2020

Patterns of dystonia ("I-D-I" and "D-I-D-") in response to l-dopa therapy for Parkinson's disease

1 reference

12 December 2020

Clinical usefulness of apomorphine in movement disorders.

1 reference

12 December 2020

The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys.

1 reference

12 December 2020

Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group

1 reference

12 December 2020

Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms

1 reference

12 December 2020

Pathophysiology of movement disorders studied using PET.

1 reference

12 December 2020

Low-dose clozapine improves dyskinesias in Parkinson's disease

1 reference

12 December 2020

Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group

1 reference

12 December 2020

The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa

1 reference

12 December 2020

Influence of fluctuations of plasma large neutral amino acids with normal diets on the clinical response to levodopa

1 reference

12 December 2020

The response to levodopa in Parkinson's disease: imposing pharmacological law and order

1 reference

12 December 2020

Effect of L-dopa on course of Parkinson's disease

1 reference

12 December 2020

Treatment of motor fluctuations in Parkinson's disease with an oral sustained-release preparation of L-dopa: clinical and pharmacokinetic observations.

1 reference

12 December 2020

Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease.

1 reference

12 December 2020

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

1 reference

12 December 2020

Current drug therapy for Parkinson's disease. A review

1 reference

12 December 2020

A six-month study of pergolide and levodopa in de novo Parkinson's disease patients

1 reference

12 December 2020

Factors that influence the occurrence of response variations in Parkinson's disease

1 reference

12 December 2020

An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines

1 reference

12 December 2020

Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double-blind single-dose study.

1 reference

12 December 2020

Dopamine agonists: the treatment for Parkinson's disease in the XXI century?

1 reference

12 December 2020

Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys

1 reference

12 December 2020

Dopamine agonists in Parkinson's disease: a look at apomorphine

1 reference

12 December 2020

Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease.

1 reference

12 December 2020

De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset

1 reference

12 December 2020

Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study

1 reference

12 December 2020

Effects of catechol-O-methyltransferase (COMT) inhibition on the pharmacokinetics of L-DOPA.

1 reference

12 December 2020